I'd say they want to see how it performs in the US market first. However, whilst earlier acquisitions do often happen, I've seen far more examples of big pharma companies waiting for post-approval before acquiring them. This includes drugs for much more debilitating conditions with little to zero alternative treatment options. Big pharma don't need to take that sort of risk to get a high return, they get the return by taking advantage of their economies of scale for commercialisation etc. So it doesn't make much sense for them to acquire before approval
- Forums
- ASX - By Stock
- Sofdra - Post approval royalties, costs and earnings
I'd say they want to see how it performs in the US market...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
28.0¢ |
Change
-0.005(1.75%) |
Mkt cap ! $441.0M |
Open | High | Low | Value | Volume |
28.5¢ | 30.8¢ | 27.8¢ | $2.808M | 9.589M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2857 | 28.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.5¢ | 77213 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2857 | 0.280 |
12 | 1099102 | 0.275 |
17 | 1181666 | 0.270 |
8 | 673922 | 0.265 |
19 | 756859 | 0.260 |
Price($) | Vol. | No. |
---|---|---|
0.285 | 77213 | 2 |
0.290 | 61615 | 3 |
0.295 | 222589 | 3 |
0.300 | 658751 | 14 |
0.305 | 201317 | 4 |
Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
Last
28.3¢ |
  |
Change
-0.005 ( 2.72 %) |
|||
Open | High | Low | Volume | ||
29.0¢ | 30.5¢ | 27.8¢ | 3452172 | ||
Last updated 15.59pm 21/05/2024 ? |
Featured News
BOT (ASX) Chart |
The Watchlist
AUQ
ALARA RESOURCES LIMITED
Stephen Gethin, Non-Executive Director & Chairman
Stephen Gethin
Non-Executive Director & Chairman
Previous Video
Next Video
SPONSORED BY The Market Online